{"title":"MicroRNA-155 in neurodegeneration","authors":"Qizhen Liu , Seyed Davar Siadat","doi":"10.1016/j.cca.2025.120506","DOIUrl":null,"url":null,"abstract":"<div><div>MicroRNA-155 (miR-155) is recognized for its multifaceted roles in neuroinflammation and neurodegeneration. This abstract explores the emerging significance of miR-155, both as an intracellular regulator and encapsulated within exosomes, as a biomarker and therapeutic target in neurodegenerative disorders. Dysregulation of miR-155 is implicated in various conditions, including Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis, where it modulates key pathways involved in neuronal survival, synaptic plasticity, and immune cell activation. Specifically, miR-155 has been shown to influence microglial activation, cytokine production, and the clearance of protein aggregates, all critical processes in neurodegenerative pathogenesis. Exosomal miR-155, released by various cell types including immune cells and neurons, offers a particularly exciting avenue. These nanovesicles facilitate intercellular communication, delivering their cargo, including miR-155, to recipient cells and influencing their function. As such, exosomal miR-155 levels in biofluids like cerebrospinal fluid and blood are being investigated as potential non-invasive diagnostic and prognostic biomarkers for neurodegenerative diseases. Furthermore, the ability of exosomes to cross the blood–brain barrier makes them attractive vehicles for targeted delivery of therapeutic agents. This review highlights the dual promise of miR-155 and exosomal miR-155: first, as readily measurable indicators of disease progression and response to treatment, and second, as actionable targets for novel therapeutic strategies aimed at modulating neuroinflammation and protecting neuronal integrity.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"578 ","pages":"Article 120506"},"PeriodicalIF":2.9000,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinica Chimica Acta","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0009898125003857","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
MicroRNA-155 (miR-155) is recognized for its multifaceted roles in neuroinflammation and neurodegeneration. This abstract explores the emerging significance of miR-155, both as an intracellular regulator and encapsulated within exosomes, as a biomarker and therapeutic target in neurodegenerative disorders. Dysregulation of miR-155 is implicated in various conditions, including Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis, where it modulates key pathways involved in neuronal survival, synaptic plasticity, and immune cell activation. Specifically, miR-155 has been shown to influence microglial activation, cytokine production, and the clearance of protein aggregates, all critical processes in neurodegenerative pathogenesis. Exosomal miR-155, released by various cell types including immune cells and neurons, offers a particularly exciting avenue. These nanovesicles facilitate intercellular communication, delivering their cargo, including miR-155, to recipient cells and influencing their function. As such, exosomal miR-155 levels in biofluids like cerebrospinal fluid and blood are being investigated as potential non-invasive diagnostic and prognostic biomarkers for neurodegenerative diseases. Furthermore, the ability of exosomes to cross the blood–brain barrier makes them attractive vehicles for targeted delivery of therapeutic agents. This review highlights the dual promise of miR-155 and exosomal miR-155: first, as readily measurable indicators of disease progression and response to treatment, and second, as actionable targets for novel therapeutic strategies aimed at modulating neuroinflammation and protecting neuronal integrity.
期刊介绍:
The Official Journal of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC)
Clinica Chimica Acta is a high-quality journal which publishes original Research Communications in the field of clinical chemistry and laboratory medicine, defined as the diagnostic application of chemistry, biochemistry, immunochemistry, biochemical aspects of hematology, toxicology, and molecular biology to the study of human disease in body fluids and cells.
The objective of the journal is to publish novel information leading to a better understanding of biological mechanisms of human diseases, their prevention, diagnosis, and patient management. Reports of an applied clinical character are also welcome. Papers concerned with normal metabolic processes or with constituents of normal cells or body fluids, such as reports of experimental or clinical studies in animals, are only considered when they are clearly and directly relevant to human disease. Evaluation of commercial products have a low priority for publication, unless they are novel or represent a technological breakthrough. Studies dealing with effects of drugs and natural products and studies dealing with the redox status in various diseases are not within the journal''s scope. Development and evaluation of novel analytical methodologies where applicable to diagnostic clinical chemistry and laboratory medicine, including point-of-care testing, and topics on laboratory management and informatics will also be considered. Studies focused on emerging diagnostic technologies and (big) data analysis procedures including digitalization, mobile Health, and artificial Intelligence applied to Laboratory Medicine are also of interest.